Skip to content

L · 0SAN.L · DRUG MANUFACTURERS - SPECIALTY & GENERIC

Sandoz Group AG

$84.74as of 2026-11-13 · Mkt cap 27.79B

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Healthcare · Drug Manufacturers - Specialty & Generic Rotkreuz 6343 sandoz.com

How the business is doing

Fiscal 2020–2025, USD

Revenue
$11.6B+5.1% 5y CAGRd
20202025
Net income
$957.5M+17.2% 5y CAGRd
20202025
Free cash flow
$1.15B+9.9% 5y CAGRd
20202025
Total equity
$9.38B+6.6% 5y CAGRd
20202025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Financials

Statements by fiscal year

USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Sandoz Group AG

        Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. It develops, manufactures, and markets finished dosage forms of small molecule pharmaceuticals to third parties. It also provides protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services; and anti-infectives, such as active pharmaceutical ingredients and intermediates primarily antibiotics. The company was founded in 1886 and is headquartered in Rotkreuz, Switzerland.

        CEO
        Richard Saynor
        Employees
        22.05K
        Beta
        0.53

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.